Advertisement
Advertisement
U.S. markets open in 8 hours 38 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Abbott Laboratories (ABT)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
96.76-1.53 (-1.56%)
At close: 04:03PM EDT
96.77 +0.01 (+0.01%)
After hours: 07:51PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close98.29
Open98.71
Bid0.00 x 1300
Ask0.00 x 900
Day's Range96.67 - 99.50
52 Week Range96.67 - 142.60
Volume6,728,558
Avg. Volume4,713,676
Market Cap169.448B
Beta (5Y Monthly)0.71
PE Ratio (TTM)20.20
EPS (TTM)4.79
Earnings DateOct 18, 2022 - Oct 24, 2022
Forward Dividend & Yield1.88 (1.94%)
Ex-Dividend DateOct 13, 2022
1y Target Est124.94
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-20% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ABT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Abbott Laboratories
    Weekly Stock ListLast week was the busiest of the quarter for earnings, with many sharp stock-price moves following above- or below-consensus results or changes in guidance. Through July 26, Refinitiv noted that 133 S&P 500 companies had reported earnings, with 76% beating expectations, above the long-term average of 66%. The blended (actual for those reporting and consensus for those still to report) growth rate is 6.2%, near the 5.6% expectation and indicating the "beats" have not been robust. But the sour mood coming into the quarter is being greeted with relief that profit shortfalls and lowered guidance are not rampant. Our analysts always look for companies that boost outlooks during earnings season. Raising guidance can be a catalyst for strong returns in the quarters ahead. Here is an initial list of BUY-rated companies in Argus coverage with raised guidance or increased outlooks during the 2Q22 EPS reporting season.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • Reuters

    UPDATE 1-Bubs Australia seeks permanent market access from U.S. FDA

    Baby formula maker Bubs Australia Ltd said on Monday it is seeking permanent access to the U.S. market after the Food and Drug Administration (FDA) spelled out how companies that have been filling a temporary shortage can become long-term suppliers. Bubs said it had lodged a letter of intent with the U.S. FDA for permanent market access to October 2025 and beyond, adding that the FDA will issue a letter of acknowledgement in response. Global infant formula manufacturers have been importing goods into the United States after the country's health regulator relaxed its import policy to address a nationwide shortage partly triggered by Abbott Laboratories' manufacturing plant in Michigan recalling some products in February.

  • ACCESSWIRE

    Our Steps Toward a More Diverse and Inclusive World

    For more than 130 years, Abbott has been known as a company that helps people live healthier lives.

  • The Wall Street Journal

    Congress Votes to Suspend Tariffs on Baby Formula Ingredient to Boost Supply

    Lawmakers said they expected the legislation would make formula easier to find, especially for families in the WIC supplemental-nutrition program.

Advertisement
Advertisement